The Coalition for Epidemic Preparedness Innovations (CEPI) highlighted the importance of working on the preparedness stage, emphasizing the need to establish alternative clinical evidence to facilitate rapid vaccine development in alignment with the CEPI's 100-day mission.CEPI's 100-day mission refe
Shin Dong-kun, a dentist-turned-politician, criticized the Yoon Suk Yeol government’s recent decision to slash the research and development (R&D) budget for 2024, at an international bio conference in Seoul.Rep. Shin of the opposition Democratic Party is also the head of the National Assembly’s Heal
U.S. health authorities have announced the first group of drugs targeted for price cuts under its Inflation Reduction Act (IRA).Included among them are original biopharmaceutical products, including Stelara (ustekinumab) and Enbrel (etanercept), drawing the attention of Korean industry executives to
Liveome has received approval from the Australian Human Research Ethics Committee (HREC) for the phase 1 clinical trial of its microbiome drug LIV001 to treat inflammatory growth disorders.Liveome is an affiliate of Medytox, the Korean botulinum toxin maker. In September, Liveome plans to start a ph
Gencurix said Tuesday that its lung cancer companion diagnostic test has received marketing authorization from the Thai Food and Drug Administration. The approval was granted for Droplex EGFR Mutation Test v2, a liquid biopsy lung cancer companion diagnostic test.Companion diagnostic test is an esse
Pharos iBio, an AI-backed new drug developer based in Korea, said it would conduct a translational study with Johns Hopkins University School of Medicine to develop a combination therapy using its pipeline PHI-101 to treat relapsed or refractory acute myeloid leukemia (AML). A translational study in
Celltrion Group Chairman Seo Jung-jin said that after the merger between the Celltrion Group's three major affiliates is completed, he may look into an initial public offering (IPO) process for Celltrion Holdings controlling Celltrion, Celltrion Healthcare, and Celltrion Pharm.Speaking to about 3,20
Celltrion Healthcare said that more than 10 U.S. insurers have included its Avastin biosimilar Vegzelma (ingredient: bevacizumab), indicated for in their formulary listings.Vegzelma is indicated to treat six types of cancer -- metastatic colorectal cancer; recurrent or metastatic non-squamous non-sm
SK Biopharmaceuticals has transferred the commercialization rights for the Middle East and North Africa (MENA) region for the epilepsy drug cenobamate (brand name in the U.S.: Xcopri) for just 4 billion won ($2.98 million).The amount is unusually small for a licensing-out of a U.S. FDA-approved new
In a decision aimed at reinforcing its position in the pharmaceutical industry, Celltrion Inc. has announced its plan to absorb its affiliate company, Celltrion Healthcare.Celltrion is listed on Kospi, and Celltrion Healthcare, Kosdaq. The established merger ratio stands at 1 : 0.4492620 (Celltrion
GC Cell said on Thursday that its U.S. affiliate, Artiva Biotherapeutics (Artiva), has received investigational new drug (IND) approval from the FDA for the phase 1 clinical trial of AB-101, an NK cell therapy for lupus nephritis (LN). This IND approval marks the first for an allogeneic CAR-T or NK
The 2023 Annual Meeting of the International Society for the Advancement of Spine Surgery, Asia-Pacific Section (ISASS AP 2023) opened on Wednesday for a four-day run at Conrad Hotel in Yeouido, Seoul.Korean organizers expressed hope that the conference will help speed up international cooperation t
Cellivery has received a “disclaimer” of opinion on the first half-year report from its auditor. The company's shares are suspended from trading, drawing the industry's attention to its delisting from the stock market.In a public notice on Monday, the new drug developer said it had received a “discl
Investment in bio and medical ventures in the first half of 2023 was less than half of the same period of last year.According to the Ministry of SMEs and Startups, investment in bio and medical ventures totaled 596.1 billion won ($448.1 million) in the first half of this year, down 54.7 percent from
Researchers from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) published a study revealing the mechanism responsible for the decline in intestinal function in patients with inflammatory bowel disease (IBD) caused by fine particulate matter (PM10).Fine particulate matter, commo
Samsung Biologics filed an injunction against Lotte Biologics and three of its former employees to stop them from moving to Lotte Biologics.Newsis, a local media outlet, reported that Samsung filed for an injunction against Lotte BioLogics and three former employees at the Seoul Eastern District Cou
Lotte Biologics said on Wednesday that it signed a memorandum of understanding (MOU) with Roche Diagnostics to advance its contract development and manufacturing (CDMO) business. Last month, Lotte Biologics signed a four-way memorandum of understanding (MOU) with Lotte Holdings, Incheon Metropolitan
A rare disease drug developed using artificial intelligence has been used in the clinical site to treat patients. Market expectations are high as it confirms the possibility of developing new drugs using AI.Pharos iBio said Thursday that it received approval for the therapeutic use of PHI-101, a tre
Samsung Bioepis is reportedly considering acquiring the biosimilar division of Biogen, according to industry sources Wednesday.Biogen put its biosimilar division up for sale to focus on developing new drugs, including Alzheimer's disease treatment Leqembi, earlier this year.If Samsung Bioepis decide
KoBioLabs has suspended the phase 2a clinical trial of its ulcerative colitis (UC) drug candidate KBL697 (pipeline name: KBLP-007).KoBioLabs said in a public notice last Wednesday that it had voluntarily withdrawn its phase 2a clinical trial of KBL697. In July 2021, KoBioLab received approval for it